EOLS Earnings — Evolus, Inc. Common Stock Post-ER Performance | BigEarnings
EOLS — Evolus, Inc. Common Stock
XNAS · Healthcare · Drug Manufacturers - Specialty & Generic
Price$6.56
Market Cap$432.0M
P/E—
52W Range$3.86 – $10.62
Next Earnings2026-08-04
About Evolus, Inc. Common Stock
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
